Home＞REGULATORY
3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing(May.17.2017)
FPMAJ Chairman Masayo Tada (left), JPMA President Yoshihiko Hatanaka |
Three major pharma trade groups of Japan, the US, and Europe all pressed for a scheme to keep NHI drug prices for the duration of the patent term at a hearing of a key drug pricing panel on May 17 - aiming to turn the tide amid a growing headwind for the so-called price maintenance premium ...
(LOG IN FOR FULL STORY)
-
Maintain Prices for On-Patent Drugs, Off-Year Revisions Should Only Cover Limited Products: FPMAJ
May.19
-
JPWA Calls for Off-Year Surveys Covering All Products: Chuikyo Hearing
May.19
-
JGA Calls for Elimination of Price Bracket Grouping Rule for Listed Generics
May.19
-
FPMAJ, EFPIA See Need to Revisit Cost-Based Pricing Method: Chuikyo
May.18
-
(Update) 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May.18
-
Japan Drug Market Could Shrink Annual 1.5% by FY2026: EFPIA Simulation
May.17
-
Continue Price Maintenance Scheme without Shedding Eligible Products: PhRMA
May.17
-
-
PMDA’s Review-Related Ordinary Loss Nearly Doubled in FY2016
Jun.28
-
MHLW Calls for Drafting Guidelines on Polypharmacy in the Elderly
Jun.27
- 6 APIs Added to List of “Switch OTC” Candidates: MHLW Jun.26
- MHLW Redefines Drug Makers’ 3 Key Officer System Jun.26
- Boxed Warning to Be Erased from Label of Pfizer Smoking Cessation Aid Champix Jun.26
- AbbVie Japan Set to Build Up Organization to Gear Up for Oncology Drug Launches: President(Jun.28)
- Japan Sales of Global Pharmas Dipped in 2016? Price Cuts, Sluggish LLPs Weighs: Jiho Tally(Jun.28)
- Drug Makers Moving to Outsource “Pharmaceutical Scouting” to Seek Efficiency: Ex-Sanofi Exec(Jun.28)
- PMDA’s Review-Related Ordinary Loss Nearly Doubled in FY2016(Jun.28)
- Stivarga OK’ed for 2nd-Line HCC, Oldamin for Gastric Varices, Actemra for Shorter Dose Interval(Jun.27)
